Evaluating a multi-vaccine respiratory immunization strategy involving SARS-CoV-2, pneumococcal, and influenza vaccines in adults: A randomized, open-label, multicenter, controlled, non-inferiority Phase IV trial in China.
Xuanwen Shi, Shasha Han, Cong Wu et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, open-label, multicenter Phase IV trial in China assessed immunogenicity and safety when adults aged ≥18 years received an inactivated SARS-CoV-2 vaccine with PPV23 and IIV4, compared with separate vaccine schedules. Among 1,404 participants randomized to three groups, co-administration preserved humoral responses across vaccine platforms. Non-inferiority was demonstrated for SARS-CoV-2 neutralizing antibody and pneumococcal serotype-specific IgG geometric mean titers or concentrations. Seroconversion findings were less consistent for SARS-CoV-2 after dose two and for influenza A(H1N1). No vaccine-related serious adverse events were reported.
Key findings
- Non-inferiority was demonstrated for SARS-CoV-2 neutralizing antibody and pneumococcal serotype-specific IgG geometric mean titers or concentrations.
- Pneumococcal seroconversion rates were non-inferior for all serotypes; results were less consistent for SARS-CoV-2 after dose two and influenza A(H1N1).
- Co-administration had an acceptable safety profile, with slightly higher rates of mild, transient local reactions and no vaccine-related serious adverse events.
Why it matters
Co-administration could simplify adult immunization against several respiratory pathogens while maintaining measured immune responses. The trial provides comparative evidence across adults aged 18 years and older, including older adults, but age- and strain-specific findings warrant cautious interpretation. Its results inform the feasibility of combined scheduling without establishing that every immune response is equivalent.
What to keep in mind
Age-stratified results showed age- and strain-specific non-inferiority findings that the authors advise interpreting cautiously; seroconversion results were also less consistent for some outcomes.